Literature DB >> 6079863

Contribution of antiviral immunity to oncolysis by Newcastle disease virus in a murine lymphoma.

M D Eaton, J D Levinthal, A R Scala.   

Abstract

Entities:  

Mesh:

Year:  1967        PMID: 6079863

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Antiviral immune cytolysis at an early stage of paramyxovirus infection.

Authors:  M D Eaton; A R Scala
Journal:  Infect Immun       Date:  1971-11       Impact factor: 3.441

2.  Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.

Authors:  Gayathri Vijayakumar; Dmitriy Zamarin
Journal:  Methods Mol Biol       Date:  2020

Review 3.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

4.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

5.  Autoimmunity induced by injection of virus-modified cell membrane antigens in syngeneic mice.

Authors:  M D Eaton; S J Almquist
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

6.  Autoimmunity induced by syngeneic splenocyte membranes carrying irreversibly adsorbed paramyxovirus.

Authors:  M D Eaton
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

Review 7.  Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.

Authors:  Vanessa Innao; Vincenzo Rizzo; Andrea Gaetano Allegra; Caterina Musolino; Alessandro Allegra
Journal:  Curr Oncol       Date:  2020-12-25       Impact factor: 3.677

8.  Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases.

Authors:  P O Vorobyev; F E Babaeva; A V Panova; J Shakiba; S K Kravchenko; A V Soboleva; A V Lipatova
Journal:  Mol Biol       Date:  2022-10-05       Impact factor: 1.540

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.